Commentary: Who is a candidate for testosterone therapy? A synthesis of international expert opinions

Journal of Sexual Medicine

Volumn 11, Issue 7, 2014, Pages 1636-1645

  Morgentaler, Abraham ^a   Khera, Mohit ^b   Maggi, Mario ^c   Zitzmann, Michael ^d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF FLORENCE   (Italy)

^d INST OF REPRO MED OF THE UNIV   (Germany)

Author keywords

Diagnosis; Evaluation; Hypogonadism; Monitoring; Testosterone; Treatment

Indexed keywords

ANDROGEN RECEPTOR; LUTEINIZING HORMONE; PROSTATE SPECIFIC ANTIGEN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ANDROGEN DEFICIENCY; ANDROGEN THERAPY; CAG REPEAT; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; CLINICAL DECISION MAKING; CLINICAL PRACTICE; CLINICAL RESEARCH; COMORBIDITY; DELAYED PUBERTY; DEPRESSION; DIABETES MELLITUS; DIAGNOSTIC TEST; ECHOGRAPHY; ERECTILE DYSFUNCTION; HEMATOCRIT; HUMAN; HYPOGONADISM; LABORATORY TEST; LIBIDO DISORDER; LIPID STORAGE; LUTEINIZING HORMONE BLOOD LEVEL; MALE INFERTILITY; METABOLIC SYNDROME X; MOOD DISORDER; MUSCLE MASS; NOTE; PATIENT COUNSELING; PATIENT MONITORING; PHYSICAL DISEASE BY BODY FUNCTION; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUESTIONNAIRE; SEXUAL DYSFUNCTION; SLEEP DISORDER; SYMPTOM; TESTIS SIZE; TESTOSTERONE BLOOD LEVEL; ADULT; CARDIOVASCULAR DISEASE; COMPLICATION; CONSENSUS DEVELOPMENT; DEFICIENCY; EXPERT WITNESS; HORMONE SUBSTITUTION; MALE; METABOLISM; MIDDLE AGED; PATIENT SELECTION; RISK FACTOR; UNITED STATES;

ADULT; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; EXPERT TESTIMONY; HORMONE REPLACEMENT THERAPY; HUMANS; LUTEINIZING HORMONE; MALE; MIDDLE AGED; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; PROSTATE-SPECIFIC ANTIGEN; RISK FACTORS; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE; UNITED STATES;

EID: 84903795358     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/jsm.12546     Document Type: Note

References (25)

1. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM; Task Force, Endocrine Society. Testosterone therapy in men with androgen deficiency syndromes: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010;95:2536-2559.
2. Wang C, Nieschlag E, Swerdloff R, etal. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. Eur Urol 2009;55:121-130.
3. Buvat J, Maggi M, Gooren L, Guay AT, Kaufman J, Morgentaler A, Schulman C, Tan HM, Torres LO, Yassin A, Zitzmann M. Endocrine aspects of male sexual dysfunctions. J Sex Med 2010;7:1627-1656.
4. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM. Testosterone therapy in adult men with androgen deficiency syndromes: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2006;91:1995-2010.
5. Powers JH. Practice guidelines: Belief, criticism, and probability. Arch Intern Med 2011;171:15-17.
6. Lazarou S, Reyes-Vallejo L, Morgentaler A. Wide variability in laboratory reference values for serum testosterone. J Sex Med 2006;3:1085-1089.
7. Corona G, Rastrelli G, Vignozzi L, Mannucci E, Maggi M. How to recognize late-onset hypogonadism in men with sexual dysfunction. Asian J Androl 2012;14:251-259.
8. Corona G, Rastrelli G, Maggi M. Diagnosis and treatment of late-onset hypogonadism: Systematic review and meta-analysis of TRT outcomes. Best Pract Res Clin Endocrinol Metab 2013;27:557-579.
9. Rastrelli G, Corona G, Vignozzi L, Maseroli E, Silverii A, Monami M, Mannucci E, Forti G, Maggi M. Serum PSA as a predictor of testosterone deficiency. J Sex Med 2013;10:2518-2528.
10. EAU Guidelines. Available at: http://www.uroweb.org/gls/pdf/17_Male_Hypogonadism_LR.pdf (accessed December 2, 2013).
11. Tajar A, McBeth J, Lee DM, Macfarlane GJ, Huhtaniemi IT, Finn JD, Bartfai G, Boonen S, Casanueva FF, Forti G, Giwercman A, Han TS, Kula K, Labrie F, Lean ME, Pendleton N, Punab M, Silman AJ, Vanderschueren D, O'Neill TW, Wu FC. European Male Aging Study Group. Elevated levels of gonadotrophins but not sex steroids are associated with musculoskeletal pain in middle-aged and older European men. Pain 2011 Jul;152:1495-1501.
12. Schneider G, Nienhaus K, Gromoll J, Heuft G, Nieschlag E, Zitzmann M. Aging males' symptoms in relation to the genetically determined androgen receptor CAG polymorphism, sex hormone levels and sample membership. Psychoneuroendocrinology 2010 May;35:578-587.
13. Francomano D, Greco EA, Lenzi A, Aversa A. CAG repeat testing of androgen receptor polymorphism: Is this necessary for the best clinical management of hypogonadism? J Sex Med 2013 Oct;10:2373-2381.
14. Liu CC, Lee YC, Wang CJ, Yeh HC, Li WM, Wu WJ, Huang CN, Bao BY, Huang CH, Huang SP. The impact of androgen receptor CAG repeat polymorphism on andropausal symptoms in different serum testosterone levels. J Sex Med 2012 Sep;9:2429-2437.
15. Wu FC, Tajar A, Beynon JM, etal. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 2010;363:123-135.
16. Vermeulen A. Hormonal cut-offs of partial androgen deficiency: A survey of androgen assays. J Endocrinol Invest 2005;28(3 suppl):28-31.
17. Huhtaniemi IT, Tajar A, Lee DM, O'Neill TW, Finn JD, Bartfai G, Boonen S, Casanueva FF, Giwercman A, Han TS, Kula K, Labrie F, Lean ME, Pendleton N, Punab M, Silman AJ, Vanderschueren D, Forti G, Wu FC, Group EMAS. Comparison of serum testosterone and estradiol measurements in 3174 European men using platform immunoassay and mass spectrometry; relevance for the diagnostics in aging men. Eur J Endocrinol 2012;166:983-991.
18. Morgentaler A. Testosterone replacement therapy and prostate cancer. Urol Clin North Am 2007;34:555-563.
19. Rastrelli G, Corona G, Lotti F, Boddi V, Mannucci E, Maggi M. Relationship of testis size and LH levels with incidence of major adverse cardiovascular events in older men with sexual dysfunction. J Sex Med 2013;10:2761-2773.
20. Vigen R, O'Donnell CI, Baron AE, etal. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 2013;310:1829-1836.
21. Finkle WD, Greenland S, Ridgeway GK, Adams JL, Frasco MA, Cook MB, Fraumeni JF Jr, Hoover RN. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS ONE 2014 Jan 29;9:e85805. doi: 10.1371/journal.pone.0085805.
22. Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: A systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med 2013;11:108.
23. Muraleedharan V, Marsh H, Kapoor D, Channer KS, Jones TH. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol 2013;169:725-733.
24. Shores MM, Smith NL, Forsberg CW, Anawalt BD, Matsumoto AM. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab 2012;97:2050-2058.
25. Incorrect number of excluded patients reported in the text and figure. JAMA 2014;311:967.